OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
OS Therapies IncorporatedAMEX: OSTX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $3.88M, compared with -$45.68K a year earlier. Trailing-twelve-month accounts payables was $12.2M. Over 3 fiscal years it compounded at +236.9% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $3.88M or moves back toward the trailing-twelve-month quarterly average of $3.05M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 8.27M USD
- Year-over-year change
- +885.5%
- 4-year CAGR
- +76.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.27M | +885.5% |
| FY2024 | 2024-12-31 | (1.05M) | -178.2% |
| FY2023 | 2023-12-31 | 1.35M | +522.7% |
| FY2022 | 2022-12-31 | 216.43K | -74.7% |
| FY2021 | 2021-12-31 | 856.48K | — |
Accounts Payables vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 accounts payables of $12.2M is the largest of the 9 companies compared; the peer median is $32K.
- Its year-over-year change of +1170.0% is the 2nd highest of 8, against a peer median of +28.5%.
- Over three fiscal years its annual growth of +236.9% compares with a peer median of +8.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.2M | +1170.0% | +236.9% | — |
| LTM Mar 2026 | $4.9M | +28.5% | +8.8% | 1472.1% | |
| LTM Jun 2026 | $3.45M | -438.7% | +104.0% | 16.4% | |
| LTM Mar 2026 | $1.88M | -646.1% | — | — | |
| LTM Mar 2026 | $764K | +6466.7% | -36.8% | — | |
| LTM Mar 2026 | $725.9K | +187.8% | -36.2% | — | |
| LTM Mar 2026 | $109.49K | -55.4% | +121.5% | 7.7% | |
| LTM Mar 2026 | $64K | +100.9% | — | 2.8% | |
| LTM Jun 2024 | $0 | — | — | 0.0% | |
| Peer median (excluding OSTX) | $32K | +28.5% | +8.8% | 7.7% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75B) |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 268.3K | 4.27B |
| Change in Working Capital | 574.67K | 947.33K | 2.02M | (129.64K) | 9.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 856.48K | 216.43K | 1.35M | (1.05M) | 8.27M |
| Other Working Capital | (281.81K) | 730.9K | 669.65K | 923.69K | 834.81K |
| Other Non-Cash Items | 2.44M | 1.51M | 2.76M | 1.46M | 9.88B |
| Operating Cash Flow | (4.4M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
| Capital Expenditures | (11.93K) | 0 | 0 | 0 | (466.42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 212.41K | 230.88K | 1.15K | 0 | (465.96M) |
| Investing Cash Flow | 200.47K | 230.88K | 1.15K | 0 | (466.42M) |
| Debt Repayment | 2.95M | 3.82M | 3.16M | 1.5M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 5.23M | 8.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (31.25M) | 0 |
| Other Financing Activities | 100K | (172.02K) | (284.18K) | 31.25M | 9.43B |
| Financing Cash Flow | 3.05M | 3.65M | 2.87M | 12.78M | 9.44B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.15M) | 90.69K | (132.5K) | 5.49M | (5.26B) |
| Free Cash Flow | (4.41M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.